0.3186

1.69% 0.0053

Ovid Therapeutics Inc (OVID)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.3133

Offen:

$0.33

24-Stunden-Volumen:

937.90K

Relative Volume:

2.03

Marktkapitalisierung:

$19.36M

Einnahmen:

$391.70K

Nettoeinkommen (Verlust:

$-52.34M

KGV:

-0.4248

EPS:

-0.75

Netto-Cashflow:

$-45.92M

1W Leistung:

+17.05%

1M Leistung:

+11.09%

6M Leistung:

-72.30%

1J Leistung:

-89.72%

1-Tages-Spanne:

$0.31

$0.3346

1-Wochen-Bereich:

$0.2701

$0.3346

52-Wochen-Spanne:

$0.2425

$3.31

Ovid Therapeutics Inc Stock (OVID) Company Profile

Firmenname

Ovid Therapeutics Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (667)

Telefon

212-776-4381

Adresse

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Mitarbeiter

Twitter

@OvidRx

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

OVID's Discussions on Twitter

Vergleichen Sie OVID mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OVID Ovid Therapeutics Inc	0.3186	19.36M	391.70K	-52.34M	-45.92M	-0.75
VRTX Vertex Pharmaceuticals Inc	450.50	113.52B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	493.22	52.93B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	300.83	39.71B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	585.93	35.00B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	255.86	26.57B	3.81B	-644.79M	-669.77M	-6.24

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-18	Herabstufung	Oppenheimer	Outperform → Perform
2024-04-30	Eingeleitet	B. Riley Securities	Buy
2024-04-29	Eingeleitet	H.C. Wainwright	Buy
2024-04-05	Eingeleitet	Wedbush	Outperform
2023-12-21	Eingeleitet	BTIG Research	Buy
2023-10-13	Eingeleitet	Oppenheimer	Outperform
2021-04-20	Herabstufung	Cantor Fitzgerald	Buy → Neutral
2021-03-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2020-12-02	Herabstufung	Citigroup	Buy → Neutral
2020-12-02	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-04	Eingeleitet	RBC Capital Mkts	Outperform
2018-04-20	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten

Jun 05, 2025

Ovid Therapeutics (OVID) to Showcase Biomarker Advances in Epile - GuruFocus

Jun 05, 2025

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 | OVID Stock News - GuruFocus

Jun 05, 2025

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 - GlobeNewswire

Jun 05, 2025

Jun 01, 2025

Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Sold by BNP Paribas Financial Markets - Defense World

Jun 01, 2025

May 30, 2025

HC Wainwright Predicts Weaker Earnings for Ovid Therapeutics - Defense World

May 30, 2025

May 28, 2025

Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $1.50 by Analysts at HC Wainwright - Defense World

May 28, 2025

Ovid Therapeutics (OVID): Price Target Revised Amid Future Growth Prospects | OVID Stock News - GuruFocus

May 27, 2025

May 20, 2025

Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) PT at $3.03 - Defense World

May 20, 2025

May 19, 2025

What is B. Riley’s Forecast for OVID Q2 Earnings? - Defense World

May 19, 2025

May 18, 2025

Q3 EPS Estimate for Ovid Therapeutics Raised by Analyst - Defense World

May 18, 2025

May 17, 2025

Wedbush Decreases Earnings Estimates for Ovid Therapeutics - Defense World

May 17, 2025

May 13, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025

Ovid Therapeutics (OVID) Exceeds Q1 Revenue Expectations and Adv - GuruFocus

May 13, 2025

Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | - GuruFocus

May 13, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 202 - GuruFocus

May 13, 2025

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 13, 2025

Ovid Therapeutics Inc Reports Q1 2025 EPS of -$0.14, Meeting Est - GuruFocus

May 13, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results | OVID Stock News - GuruFocus

May 13, 2025

Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | OVID Stock News - GuruFocus

May 13, 2025

Ovid Therapeutics Inc. SEC 10-Q Report - TradingView

May 13, 2025

Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025

May 11, 2025

Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday - Defense World

May 11, 2025

May 08, 2025

Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Purchased by Renaissance Technologies LLC - Defense World

May 08, 2025

May 06, 2025

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance

May 06, 2025

May 05, 2025

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - ADVFN

May 05, 2025

Dup15q syndrome Market: Epidemiology, Therapies, Companies, - openPR.com

May 05, 2025

Apr 27, 2025

JPMorgan Chase & Co. Decreases Stock Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Apr 27, 2025

Ovid Therapeutics (NASDAQ:OVID) Upgraded at William Blair - Defense World

Apr 27, 2025

Apr 25, 2025

Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $3.03 - Defense World

Apr 25, 2025

Apr 24, 2025